Exelixis is a Resilient Leader in the Field of Oncology Therapeutics
Our success in advancing clinical programs and establishing commercial product franchises has been fueled by our team’s unwavering belief in the science behind our molecules.
Exelixis’ flagship molecule, cabozantinib, is the origin of two commercial products, CABOMETYX® and COMETRIQ®, marketed by Exelixis in the United States. Exelixis’ third product, COTELLIC®, a formulation of cobimetinib, is marketed under a collaboration with Genentech, a member of the Roche Group.
Beyond our approved indications, these medicines are currently the focus of a robust clinical trial program, including collaborative studies to investigate multiple pathways and combination treatment regimens. Learn more about our pipeline, here.
Exelixis Strives to Give Patients Living with Cancer Hope – and a Chance for More Time
Partnering with Physicians to Put Patients First
Our commitment to utilizing the best science to develop effective treatment regimens for patients is only part of Exelixis’ equation for success. We maximize the value we bring into a physician’s office by making it as easy as possible to minimize patient burden. We collaborate with patients’ teams of healthcare providers on problem solving and deliver service in a way that aims to eliminate barriers and clear the hurdles so that those in need have access to our medicines.
Adverse Events or Product Quality Complaints
If you want to report an adverse event related to use of CABOMETYX or COMETRIQ, or if you have a CABOMETYX or COMETRIQ product quality complaint,
please call 1-855-500-3935 (EXEL).
This page is intended for U.S. residents only.
- Ipsen has an exclusive license to commercialize cabozantinib outside of the United States and Japan. Please visit www.ipsen.com for more information when available.
- Takeda has an exclusive license to commercialize cabozantinib in Japan. Please visit www.takeda.com for more information when available.